keyword
https://read.qxmd.com/read/38502852/genomic-and-immune-microenvironment-features-influencing-chemoimmunotherapy-response-in-gastric-cancer-with-peritoneal-metastasis-a-retrospective-cohort-study
#21
JOURNAL ARTICLE
Pengfei Yu, Guangyu Ding, Xingmao Huang, Chenxuan Wang, Jingquan Fang, Ling Huang, Zeyao Ye, Qi Xu, Xiaoying Wu, Junrong Yan, Qiuxiang Ou, Yian Du, Xiangdong Cheng
BACKGROUND: Patients with peritoneal metastasis (PM) from gastric cancer (GC) exhibit poor prognosis. Chemoimmunotherapy offers promising clinical benefits; however, its efficacy and predictive biomarkers in a conversion therapy setting remain unclear. The authors aimed to retrospectively evaluate chemoimmunotherapy efficacy in a conversion therapy setting for GC patients with PM and establish a prediction model for assessing clinical benefits. MATERIALS AND METHODS: A retrospective evaluation of clinical outcomes encompassed 55 GC patients with PM who underwent chemoimmunotherapy in a conversion therapy setting...
March 19, 2024: International Journal of Surgery
https://read.qxmd.com/read/38498174/frontline-treatment-of-mantle-cell-lymphoma
#22
JOURNAL ARTICLE
Christine E Ryan, Philippe Armand, Ann S LaCasce
Despite many recent therapeutic advances, mantle cell lymphoma (MCL) remains a largely incurable disease. Treatments for patients with relapsed/refractory (R/R) disease are limited in number and in response durability. Therefore, improving the efficacy of frontline (1L) treatment, and specifically maximizing the duration of first remission, remains of critical importance to obtain favorable long-term outcomes. As 1L treatments become more effective, improving tolerability is also becoming an increasingly realistic goal...
March 18, 2024: Blood
https://read.qxmd.com/read/38484730/analysis-of-treatment-related-adverse-events-and-wound-complications-of-surgical-resection-after-neoadjuvant-chemoimmunotherapy-for-non-small-cell-lung-cancer
#23
JOURNAL ARTICLE
Yihang Li, Xiaodong Hu, Ruhu Zhang, Nan Wu, Qingqing Xia, Peijie Gu
Neoadjuvant chemoimmunotherapy is becoming an increasingly important part of the management of lung cancer to facilitate surgical resection. This study aimed to summarize the treatment-related adverse events (TRAEs) and wound complications of neoadjuvant chemoimmunotherapy in non-small cell lung cancer (NSCLC). Eligible studies of neoadjuvant chemoimmunotherapy for NSCLC were identified from PubMed, Embase and Web of Science. The endpoints mainly included TRAEs and wound complications. Stata18 software was used for statistical analysis with p < 0...
March 2024: International Wound Journal
https://read.qxmd.com/read/38483781/a-podcast-on-pre-or-perioperative-chemoimmunotherapy-for-stage-iii-non-small-cell-lung-cancer-shared-agreement-from-the-thoracic-surgeon-and-oncologist-perspectives
#24
JOURNAL ARTICLE
Luca Bertolaccini, Andrea De Giglio, Eleonora Gariazzo, Giulio Metro
Management of stage II-III non-small cell lung cancer (NSCLC) has been dramatically revolutionized by studies testing the addition of immunotherapy (IO) to chemotherapy in the pre- or perioperative setting. That is because the integration of chemoimmunotherapy (chemo-IO) with surgery has consistently shown a significant improvement in pathological complete response (path CR) rate, event-free survival, and, more recently, overall survival, versus preoperative chemotherapy alone. Particularly, resectable stage III NSCLCs represent a disease entity with a high risk of distant recurrence after radical surgery, for whom pre- or perioperative chemo-IO should be considered as the preferential treatment option...
March 14, 2024: Oncology and Therapy
https://read.qxmd.com/read/38483588/prognostic-significance-of-immunohistochemical-classification-utilizing-biopsy-specimens-in-patients-with-extensive-disease-small-cell-lung-cancer-treated-with-first-line-chemotherapy-and-immune-checkpoint-inhibitors
#25
JOURNAL ARTICLE
Naoki Shijubou, Toshiyuki Sumi, Terufumi Kubo, Kenta Sasaki, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Yoshiko Keira, Kotomi Terai, Tatsuru Ikeda, Yuichi Yamada, Hirofumi Chiba, Yoshihiko Hirohashi, Toshihiko Torigoe
PURPOSE: Although immune checkpoint inhibitors (ICIs), together with cytotoxic chemotherapy (chemoimmunotherapy), have been adapted for the initial treatment of extensive-disease small-cell lung cancer (ED-SCLC), they have achieved limited success. In ED-SCLC, a subtype of SCLC, the expression of immune-related molecules and clinical data are not well understood in relation to ICI treatment efficiency. METHODS: We examined lung biopsy specimens from patients diagnosed with ED-SCLC treated with chemoimmunotherapy or chemotherapy...
March 14, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38482237/does-microbiota-composition-act-as-predictive-signature-for-the-evaluation-of-chemoimmunotherapy-response-efficacy
#26
EDITORIAL
Serena Martinelli, Ingrid Lamminpää, Amedeo Amedei
No abstract text is available yet for this article.
February 29, 2024: Journal of Gastrointestinal Oncology
https://read.qxmd.com/read/38480829/chemoimmunotherapy-combinations-translating-basic-knowledge-into-clinical-successes
#27
EDITORIAL
Lionel Apetoh
No abstract text is available yet for this article.
March 13, 2024: Genes and Immunity
https://read.qxmd.com/read/38478390/btk-inhibitors-in-cll-second-generation-drugs-and-beyond
#28
JOURNAL ARTICLE
Constantine S Tam, Philip A Thompson
BTK inhibitors (BTKi) are established standards-of-care in multiple B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma and Waldenstrom macroglobulinemia. The first-generation BTKi ibrutinib demonstrated superiority over standard chemoimmunotherapy regimens in multiple randomized trials but is limited by cardiovascular side-effects such as atrial fibrillation and hypertension. Second-generation BTKi have improved selectivity and demonstrate reduced rates of cardiovascular complications in three head-to-head ibrutinib studies...
March 13, 2024: Blood Advances
https://read.qxmd.com/read/38476308/taking-the-next-step-in-double-refractory-disease-current-and-future-treatment-strategies-for-chronic-lymphocytic-leukemia
#29
REVIEW
Manabu Hayama, John C Riches
Chronic lymphocytic leukemia (CLL) is a monoclonal B-cell lymphoproliferative disease with a high annual incidence in Western countries. As B-cell receptor (BCR) signaling and intrinsic apoptotic resistance play critical roles in the development and survival of CLL cells, therapeutic approaches targeting these pathways have been extensively investigated to tackle this incurable disease. Over the last decade, several Phase 3 trials have confirmed the superior efficacy of covalent Bruton tyrosine kinase inhibitors (cBTKis) and venetoclax, a selective B-cell lymphoma 2 (BCL2) inhibitor, over chemoimmunotherapy...
2024: OncoTargets and Therapy
https://read.qxmd.com/read/38474108/serum-soluble-cd163-levels-as-a-prognostic-biomarker-in-patients-with-diffuse-large-b-cell-lymphoma-treated-with-chemoimmunotherapy
#30
JOURNAL ARTICLE
Aspasia Koudouna, Annita Ioanna Gkioka, Alexandros Gkiokas, Thomai M Tryfou, Mavra Papadatou, Alexandros Alexandropoulos, Vassiliki Bartzi, Nikolitsa Kafasi, Marie-Christine Kyrtsonis
The majority of patients with Diffuse Large B-cell Lymphoma (DLBCL) will respond to first-line treatment and be cured. However, the disease is heterogeneous, and biomarkers able to discriminate patients with suboptimal prognosis are needed. M2 CD163-positive tumor-associated macrophages (TAMs) were shown to be implicated in DLBCL disease activity regulation. Serum-soluble CD163 (sCD163) functions as a scavenger receptor for haptoglobin-hemoglobin complexes and is mostly expressed by monocytes and macrophages...
March 1, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38473342/venetoclax-initiation-in-chronic-lymphocytic-leukemia-international-insights-and-innovative-approaches-for-optimal-patient-care
#31
REVIEW
Mary Ann Anderson, Renata Walewska, Fidelma Hackett, Arnon P Kater, Josie Montegaard, Susan O'Brien, John F Seymour, Matthew Smith, Stephan Stilgenbauer, Ashley Whitechurch, Jennifer R Brown
Venetoclax, a highly selective, oral B-cell lymphoma 2 inhibitor, provides a robust targeted-therapy option for the treatment of chronic lymphocytic leukemia (CLL), including patients with high-risk del(17p)/mutated- TP53 and immunoglobulin heavy variable region unmutated CLL and those refractory to chemoimmunotherapy across all age groups. Due to the potent pro-apoptotic effect of venetoclax, treatment initiation carries a risk of tumor lysis syndrome (TLS). Prompt and appropriate management is needed to limit clinical TLS, which may entail serious adverse events and death...
February 28, 2024: Cancers
https://read.qxmd.com/read/38472556/bladder-sparing-treatment-using-tislelizumab-combined-with-gemcitabine-cisplatin-in-selected-patients-with-muscle-invasive-bladder-cancer-a-real-world-study
#32
JOURNAL ARTICLE
Cheng Luo, Shuhang Luo, Wumier Wusimanjiang, Zongren Wang, Ping Liu, Bin Wang, Dan Yuan, Hao Lin, Abai Xu, Nan Deng, Kaihui Wu, Xuejin Zhu, Peng Xu, Junxing Chen, Bin Huang
PURPOSE: To retrospectively evaluate the tislelizumab-based chemoimmunotherapy combined with gemcitabine/cisplatin for bladder-sparing in patients with muscle-invasive bladder cancer (MIBC). METHODS: Forty-five patients who received bladder-sparing treatment or radical cystectomy (RC) for MIBC (cT2-T4a, NxM0) were retrospectively enrolled. All patients received maximal transurethral resection of bladder tumor (mTURBT), followed by four cycles of chemo-immunotherapy with tislelizumab (PD-L1 inhibitor), gemcitabine, and cisplatin...
March 12, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38469304/microrna-126-selected-with-broad-spectrum-analysis-of-micrornas-a-new-predictive-factor-for-the-effectiveness-of-immunotherapy-or-chemoimmunotherapy-in-advanced-nsclc-patients
#33
JOURNAL ARTICLE
Anna Grenda, Barbara Kuźnar-Kamińska, Ewa Kalinka, Paweł Krawczyk, Marek Sawicki, Agata Filip, Izabela Chmielewska, Małgorzata Frąk, Natalia Krzyżanowska, Janusz Milanowski
INTRODUCTION: Expression of PD-L1 on cancer cells is the only validated predictive factor for immunotherapy in NSCLC (Non-Small Cell Lung Cancer) patients. However, on this basis, it is difficult to predict the occurrence of resistance to immune checkpoint inhibitors (ICIs). MicroRNAs are widely studied as biomarkers of cancers. Our study was designed to determine whether microRNAs can be sensitive predictive factors in the qualification of NSCLC patients to first-line immunotherapy or chemoimmunotherapy...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38469299/cd8-nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma
#34
JOURNAL ARTICLE
Lourdes Hontecillas-Prieto, Daniel J García-Domínguez, Natalia Palazón-Carrión, Alejandro Martín García-Sancho, Esteban Nogales-Fernández, Carlos Jiménez-Cortegana, María L Sánchez-León, Silvia Silva-Romeiro, Rocío Flores-Campos, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fátima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Antonio Salar-Silvestre, Delvys Rodríguez-Abreu, Laura Gálvez-Carvajal, Jorge Labrador, María Guirado-Risueño, Mariano Provencio-Pulla, Margarita Sánchez-Beato, Lejeune Marylene, Tomás Álvaro-Naranjo, María Casanova-Espinosa, Antonio Rueda-Domínguez, Víctor Sánchez-Margalet, Luis de la Cruz-Merino
BACKGROUND: Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients DLBCL relapses, and therefore, especially in this setting, the search for new prognostic and predictive biomarkers is an urgent need. Natural killer (NK) are effector cells characterized by playing an important role in antitumor immunity due to their cytotoxic capacity and a subset of circulating NK that express CD8 have a higher cytotoxic function...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38467604/neoadjuvant-chemo-immunotherapy-with-camrelizumab-plus-nab-paclitaxel-and-cisplatin-in-resectable-locally-advanced-squamous-cell-carcinoma-of-the-head-and-neck-a-pilot-phase-ii-trial
#35
JOURNAL ARTICLE
Di Wu, Yong Li, Pengfei Xu, Qi Fang, Fei Cao, Hongsheng Lin, Yin Li, Yong Su, Lixia Lu, Lei Chen, Yizhuo Li, Zheng Zhao, Xiaoyu Hong, Guohong Li, Yaru Tian, Jinyun Sun, Honghong Yan, Yunyun Fan, Xinrui Zhang, Zhiming Li, Xuekui Liu
Neoadjuvant chemoimmunotherapy has emerged as a potential treatment option for resectable head and neck squamous cell carcinoma (HNSCC). In this single-arm phase II trial (NCT04826679), patients with resectable locally advanced HNSCC (T2‒T4, N0‒N3b, M0) received neoadjuvant chemoimmunotherapy with camrelizumab (200 mg), nab-paclitaxel (260 mg/m2 ), and cisplatin (60 mg/m2 ) intravenously on day one of each three-week cycle for three cycles. The primary endpoint was the objective response rate (ORR)...
March 11, 2024: Nature Communications
https://read.qxmd.com/read/38467131/activity-of-venetoclax-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukaemia-analysis-of-the-venice-1-multicentre-open-label-single-arm-phase-3b-trial
#36
JOURNAL ARTICLE
Arnon P Kater, Önder Arslan, Fatih Demirkan, Yair Herishanu, Burhan Ferhanoglu, Marcos Gonzalez Diaz, Brian Leber, Marco Montillo, Panayiotis Panayiotidis, Davide Rossi, Alan Skarbnik, Adrian Tempescul, Mehmet Turgut, Clemens H Mellink, Anne-Marie F van der Kevie-Kersemaekers, Stuart Lanham, Ben Sale, Luis Del Rio, Relja Popovic, Brenda J Chyla, Todd Busman, Viktor Komlosi, Xifeng Wang, Kavita Sail, German E Pena, Tamas Vizkelety, Francesco Forconi
BACKGROUND: Most patients with chronic lymphocytic leukaemia progress after treatment or retreatment with targeted therapy or chemoimmunotherapy and have limited subsequent treatment options. Response levels to the single-agent venetoclax in the relapsed setting is unknown. We aimed to assess venetoclax activity in patients with or without previous B-cell receptor-associated kinase inhibitor (BCRi) treatment. METHODS: This multicentre, open-label, single-arm, phase 3b trial (VENICE-1) assessed activity and safety of venetoclax monotherapy in adults with relapsed or refractory chronic lymphocytic leukaemia, stratified by previous exposure to a BCRi...
March 8, 2024: Lancet Oncology
https://read.qxmd.com/read/38464519/prognostic-impact-of-clinical-factors-for-immune-checkpoint-inhibitor-with-or-without-chemotherapy-in-older-patients-with-non-small-cell-lung-cancer-and-pd-l1-tps-%C3%A2-50
#37
JOURNAL ARTICLE
Shota Takei, Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, Yoshiki Negi, Yasuhiro Goto, Akira Nakao, Shinsuke Shiotsu, Keiko Tanimura, Takayuki Takeda, Asuka Okada, Taishi Harada, Koji Date, Yusuke Chihara, Isao Hasegawa, Nobuyo Tamiya, Yuki Katayama, Naoya Nishioka, Kenji Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Takashi Kijima, Koichi Takayama
INTRODUCTION: The proportion of older patients diagnosed with advanced-stage non-small cell lung cancer (NSCLC) has been increasing. Immune checkpoint inhibitor (ICI) monotherapy (MONO) and combination therapy of ICI and chemotherapy (COMBO) are standard treatments for patients with NSCLC and programmed cell death ligand-1 (PD-L1) tumor proportion scores (TPS) ≥ 50%. However, evidence from the clinical trials specifically for older patients is limited. Thus, it is unclear which older patients benefit more from COMBO than MONO...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38463231/prognostic-value-of-inflammatory-nutritional-scores-in-locally-advanced-esophageal-squamous-cell-carcinoma-patients-undergoing-neoadjuvant-chemoimmunotherapy-a-multicenter-study-in-china
#38
JOURNAL ARTICLE
Jinxin Xu, Zhinuan Hong, Yingjie Cai, Zhen Chen, Jingping Lin, Xi Yuan, Shuchen Chen, Jinbiao Xie, Mingqiang Kang, Sunkui Ke
OBJECTIVE: This study investigates the prognostic significance of inflammatory nutritional scores in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC) undergoing neoadjuvant chemoimmunotherapy. METHODS: A total of 190 LA-ESCC patients were recruited from three medical centers across China. Pre-treatment laboratory tests were utilized to calculate inflammatory nutritional scores. LASSO regression and multivariate logistic regression analyses were conducted to pinpoint predictors of pathological response...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38461929/evaluation-of-mpr-and-pcr-as-surrogate-endpoints-for-survival-in-randomized-controlled-trials-of-neoadjuvant-immune-checkpoint-blockade-in-resectable-in-non-small-cell-lung-cancer
#39
JOURNAL ARTICLE
Jacobi B Hines, Robert B Cameron, Alessandra Esposito, Leeseul Kim, Luca Porcu, Antonio Nuccio, Giuseppe Viscardi, Roberto Ferrara, Giulia Veronesi, Patrick M Forde, Janis Taube, Everett Vokes, Christine M Bestvina, James M Dolezal, Matteo Sacco, Marta Monteforte, Tina Cascone, Marina C Garassino, Valter Torri
INTRODUCTION: Controversy remains as to whether pathologic complete response (pCR) and major pathologic response (MPR) represent surrogate endpoints for event free survival (EFS) and overall survival (OS) in neoadjuvant trials for resectable non-small cell lung cancer (NSCLC). METHODS: A search of PubMed and archives of international conference abstracts was performed from June 2017 through October 31, 2023. Studies incorporating a neoadjuvant arm with immune checkpoint blockade alone or in combination with chemotherapy were included...
March 8, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38455694/aplastic-anaemia-associated-with-bendamustine-therapy-a-rare-side-effect
#40
JOURNAL ARTICLE
Salman Khan, Ekrem Yetiskul, Malik Waleed Zeb Khan, Gabriel Chavez Reyna, Amanda Matra, Georges Khattar, Marcel A Odaimi
INTRODUCTION: During treatment for malignant lymphoma, cytopenia can develop for several reasons. This can range from mild cytopenias leading to infection and bleeding to full-blown drug-induced aplastic anaemia. While aplastic anaemia affects individuals of all genders and ages, here, we describe aplastic anaemia after chemotherapy exposure to bendamustine in a 65-year-old female with non-Hodgkin's lymphoma. CASE DESCRIPTION: A 65-year-old woman with recurrent indolent marginal zone lymphoma and post-chemotherapy with bendamustine and rituximab, presented with a neutropenic fever and was admitted with a leading diagnosis of sepsis...
2024: European Journal of Case Reports in Internal Medicine
keyword
keyword
28305
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.